Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide Tablet, Film Coated
FDA Label NDC 49884-787

37 label sections · Submitted to the FDA by Par Health Usa, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Par Health Usa, Llc for the product Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide (NDC 49884-787). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: fetal toxicity, 1 indications and usage, 2 dosage and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 fetal toxicity, 5.2 hypotension in volume-or salt-depleted patients, 5.3 increased angina and/or myocardial infarction, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.